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Amyotrophic lateral sclerosis is a late-onset progres-
sive neurodegenerative disease affecting motor
neurons. The etiology of most ALS cases remains
unknown, but 2% of instances are due to mutations
in Cu/Zn superoxide dismutase (SOD1). Since spo-
radic and familial ALS affects the same neurons with
similar pathology, it is hoped that therapies effective
in mutant SOD1 models will translate to sporadic
ALS. Mutant SOD1 induces non-cell-autonomous
motor neuron killing by an unknown gain of toxicity.
Selective vulnerability of motor neurons likely arises
from a combination of several mechanisms, including
protein misfolding, mitochondrial dysfunction, oxida-
tive damage, defective axonal transport, excitotoxic-
ity, insufficient growth factor signaling, and inflamma-
tion. Damage within motor neurons is enhanced by
damage incurred by nonneuronal neighboring cells,
via an inflammatory response that accelerates disease
progression. These findings validate therapeutic ap-
proaches aimed at nonneuronal cells.
Introduction
It has been over 135 years since the great French neuro-
biologist and clinician Jean-Martin Charcot (Charcot
and Joffroy, 1869) first described the progressive, late-
onset motor neuron disease Amyotrophic lateral sclero-
sis (ALS). With premature degeneration and death of up-
per and lower motor neurons provoking fatal paralysis
as its salient clinical features, the name of the disease
derives from Charcot’s observation in the lateral por-
tions of the spinal cord of a distinct ‘‘myelin pallor’’ rep-
resenting degeneration and loss of the axons of upper
motor neurons as they descend from the brain to con-
nect directly or indirectly onto the lower motor neurons
within the spinal cord. Initially known as Charcot’s scle-
rosis and now more familiarly known in the United States
as Lou Gehrig’s disease, onset of disease is in midlife
(usually between age 45 and 60), with a typical disease
course of one to five years. Consideration of incidence
(frequency of new cases per year) and prevalence (the
proportion of affected individuals in the population;
1–2 and 4–6 per 100,000, respectively) understates the
impact of ALS, with the lifetime risk at about 1 in 1000
(Mitsumoto et al., 1998; Yoshida et al., 1986).
Most incidences (90%) of ALS are sporadic, that is,
without an obvious genetic component. Approximately
10% are inherited in a dominant manner (and referred
to as familial ALS). Sporadic and familial ALS produce
*Correspondence: dcleveland@ucsd.edusimilar pathological hallmarks, including progressive
muscle weakness, atrophy, and spasticity, each of which
reflects the degeneration and death of upper and lower
motor neurons. Denervation of the respiratory muscles
and diaphragm is generally the fatal event. Despite
intense effort, very limited therapeutic options have
emerged for slowing disease course, although advances
have been made in palliative therapy.
We review here what has been learned about new
genes, the current models of pathogenesis, and summa-
rize directions now being undertaken for promising new
therapies.
Genetics of ALS
Most incidences of ALS are sporadic but w10% of pa-
tients have a familial history. The identified chromo-
somal loci containing the mutations leading to ALS-like
human motor neuron diseases (Table 1) have been de-
fined as ALS1 through ALS8, as well as ALS with fronto-
temporal dementia (ALS-FTD) and ALS-FTD coupled
with Parkinson’s disease (ALS-FTDP). Mutations in
genes encoding angiogenin (ANG) and VEGF and se-
quence variants in neurofilament genes have also been
reported (for more detailed consideration of the genet-
ics, see Gros-Louis et al. [2006]). Although all have in
common disease that affects motor neurons, the no-
menclature is misleading since only ALS1, ALS3, ALS6,
ALS7, mutations in angiogenin and VEGF, and a small
proportion of incidences of ALS8 represent the classic
late-onset neurodegenerative disease with selective kill-
ing of upper and lower motor neurons leading to pro-
gressive paralysis. ALS-FTD and ALS-FTDP are likely
appropriately classified as bona fide ALS, but patients
have additional disease features including dementia
and dystonia. For all of these disease incidences, only
the genes responsible for ALS1, ALS8, and ALS-FTDP
have been identified.
ALS1—Mutation in SOD1
The lion’s share of work has focused on ALS1 caused
by mutations in Cu/Zn superoxide dismutase (SOD1).
Mutations in the SOD1 gene are the most common
form of inherited ALS, accounting forw20% of all the fa-
milial ALS forms and corresponding to 1%–2% of all ALS
cases. Since the firstSOD1missense mutations were re-
ported in 1993 (Rosen et al., 1993), the number of known
mutations has increased to more than 114. These are
distributed throughout all five exons encoding the 153
amino acid protein, with no region of the polypeptide es-
caping disease causing mutation. With the exception of
a few instances, all SOD1 mutations are dominant.
Sporadic and SOD1mutant-mediated familial ALS are
clinically indistinguishable and affect the same neurons,
but even within the familial forms, the time of onset and
length of disease vary. The alanine-to-valine substitu-
tion at position 4 of SOD1 (SOD1A4V) is the most promi-
nent mutation in North America, responsible for w50%
of cases, and has a uniformly aggressive disease course
with a mean survival of only 1 year after onset. Mice and
rats expressing mutant forms of human or mouse SOD1
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40Table 1. Genetics of Human ALS and Other Motor Neuron Diseases Sometimes Referred to as ALS
Disease Locus Gene (Protein/Function) Heredity Onset Reference
Typical ALS
ALS1 21q22.1 SOD1 (Cu/Zn superoxide
dismutase). Converts
superoxide to water
or hydrogen peroxide.
Dominant Adult (Rosen et al., 1993)
ALS3 18q21 Unknown Dominant Adult (Hand et al., 2002)
ALS6 16q12 Unknown Dominant Adult (Abalkhail et al., 2003;
Ruddy et al., 2003;
Sapp et al., 2003)
ALS7 20p13 Unknown Dominant Adult (Sapp et al., 2003)
ALS with Dementia
ALS-FTD 9q21–22 Unknown Dominant Adult ALS with
frontotemporal
dementia (FTD)
(Hosler et al., 2000;
Ostojic et al., 2003)
ALS-FTDP 17q21.1 MAPT (Tau) Microtubule-
associated protein.
Dominant Adult ALS with FTD and
Parkinson’s Disease
(Clark et al., 1998;
Hutton et al., 1998)
Atypical ALS
ALS8 20q13.3 VAPB (VAMP-associated
protein B). May be involved
in vesicular trafficking.
Interacts with itself,
VAMP-A, and
synaptobrevins.
Dominant Adult. Heterogeneous disease
(most cases are ALS with
tremor; few cases are
typical ALS; 25% of
cases are late-onset
spinal muscular atrophy)
(Nishimura et al., 2004a,
2004b)
Progressive
lower motor
neuron
disease
2p13 DCTN1 (Dynactin subunit
p150glued). Axonal transport
of cellular organelles
and proteins.
Dominant Adult. Vocal-fold paralysis;
weakness and muscle
atrophy of hands and
facial muscles
(Puls et al., 2003)
Other Motor Neuron Diseases Sometimes Referred to as ALS
ALS2 2q33 ALS2 (ALS2/Alsin). Endosomal
dynamics. Guanine exchange
factor for Rab5 and Rac1.
Recessive Juvenile Heterogeneous
disease (95% of cases
are infantile-onset)
(Hadano et al., 2001;
Hentati et al., 1994;
Yamanaka et al., 2006;
Yang et al., 2001)
ALS4 9q34 SETX (Senataxin). Putative
DNA/RNA helicase.
Dominant Juvenile (Recessive
mutations cause
ataxia-oculomotor
apraxia type 2)
(Chance et al., 1998;
Chen et al., 2004)
ALS5 15q15.1–
q21.1
Unknown Recessive Juvenile (Hentati et al., 1998)develop progressive motor neuron degeneration (Bruijn
et al., 1997; Gurney et al., 1994; Howland et al., 2002;
Jonsson et al., 2004; Nagai et al., 2001; Ripps et al.,
1995; Wang et al., 2003, 2005; Wong et al., 1995), and
most of our knowledge on mechanisms of motor neuron
pathology in ALS is from studies using these models
(see below).
Vascular Endothelial Growth Factor (VEGF)
Vascular endothelial growth factor (VEGF), an estab-
lished regulator of developmental, hypoxia-induced,
and tumor-induced angiogenesis, gained interest as
a contributor to ALS when deletion of the hypoxia re-
sponse element (HRE) in the murine VEGF promoter re-
sulted in ALS-like disease in mice (Oosthuyse et al.,
2001). VEGF is widely expressed throughout the central
nervous system (CNS) and can function as a neurotro-
phic factor for multiple neuronal cell types, including
motor neurons (Oosthuyse et al., 2001; Van Den Bosch
et al., 2004). Screening of ALS patient DNAs in promoter
regions of the VEGF gene, including the HRE and re-
gions known to correlate with downregulation of VEGFsynthesis, found no link between HRE variants and dis-
ease (Gros-Louis et al., 2003; Lambrechts et al., 2003).
Two haplotypes in other regions of the promoter, how-
ever, showed an increased risk of developing ALS in
a Belgian, Swedish, and a British/Birmingham popula-
tion (Lambrechts et al., 2003), but this has not been con-
firmed in other populations (Chen et al., 2006; Terry
et al., 2004; Van Vught et al., 2005).
Angiogenin (ANG)
Mutations in ANG have also been linked to ALS, empha-
sizing a potential link between altered angiogenesis and
motor neuron degeneration. Seven missense mutations
were identified in 15 patients with familial ALS and 11 ap-
parently sporadic ALS patients (Greenway et al., 2006).
However, these mutations seem restricted to Irish and
Scottish populations, as they were not found in English,
Swedish, and North American populations and therefore
suggest that ALS-linked ANG mutations are rare. The
manner in which the identified mutations affect angioge-
nin function and provoke motor neuron disease is still
unknown. Angiogenin, which is expressed within the
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clear RNase activity that can facilitate rRNA synthesis, at
least in endothelial cells. Interestingly, the majority of the
mutations found in ALS patients are located within the
catalytic core, and one of them is in the nuclear localiza-
tion signal, both predicting a loss of function of the
mutated angiogenin, although this remains to be con-
firmed. Whether angiogenin is endowed with neurotro-
phic properties like VEGF, in addition to its angiogenic
activity, is not yet established.
ALS8—VAMP-Associated Protein B (VAPB)
A dominant missense mutation on chromosome 20 in
a set of seven kindreds has been linked to a heteroge-
neous disease course, with most instances of disease
representing an atypical ALS that is accompanied by
an unusual tremor (Nishimura et al., 2004a). About one-
fourth of affected individuals in the same families de-
velop a late-onset spinal muscular atrophy, and a small
proportion of patients develop symptoms of classic
ALS. All instances apparently derive from a common
mutation in the gene encoding vesicle-associated
membrane protein B (VAPB), also known as synaptobre-
vin-associated protein B. VAPB has been implicated in
endoplasmic reticulum to Golgi transport, albeit other
roles in membrane transport, including axonal transport
of membrane components, are likely as well. It is un-
known how the corresponding proline-to-serine substi-
tution at position 56 affects the functional properties of
the ubiquitously expressed VAPB.
Neuronal Intermediate Filaments
The genes encoding the three neurofilament subunits
have long been suspected as causative for ALS because
of their link with motor neuron pathology in mice and
humans. Initial evidence fueling this suspicion was the
realization that aberrant neurofilament accumulations
are a pathological hallmark of both familial and sporadic
ALS (Hirano, 1991; Hirano et al., 1984a, 1984b) and are
also seen in ALS mice expressing mutant SOD1 (Bruijn
et al., 1997; Dal Canto and Gurney 1994). In addition,
mice with increased levels of wild-type NF-H or NF-L
subunits develop age-dependent motor neuron pathol-
ogy (Cote et al., 1993; Xu et al., 1993), while expression
of a point mutation in NF-L at levels corresponding to
that expected for dominantly inherited disease pro-
duces fatal, progressive paralysis (Lee et al., 1994).
Despite this, exhaustive screening for mutations in the
three neurofilament genes in patient DNAs failed to yield
conclusive linkage to either sporadic or familial ALS
patients (Garcia et al., 2006), although dominant point
mutations in NF-L have been linked to a milder motor
neuron disease, Charcot-Marie-Tooth (CMT) disease
(De Jonghe et al., 2001; Jordanova et al., 2003). Never-
theless, in-frame insertions or deletions within the nor-
mal array of 44 or 45 KSP repeats in the tail domain of
the NF-H subunit have been reported in w1% of spo-
radic ALS patients (Al-Chalabi et al., 1999; Figlewicz
et al., 1994; Tomkins et al., 1998). Collectively, it is likely
that these neurofilament variants are risk factors for ALS
and/or a primary event with low penetrance.
A final potential contribution of neurofilaments to ALS
comes from errors in the expression of an additional
intermediate filament subunit, peripherin. An assembly-disrupting frameshift mutation has been reported in one
sporadic ALS case (Gros-Louis et al., 2004). A proposal
for the involvement of a peripherin variant, in which an
intronic sequence is retained in the final mRNA that
is produced during the disease course, may also con-
tribute to human disease (Robertson et al., 2003), albeit
deletion of the peripherin gene has no affect on disease
course in mice having an ALS-causing SOD1 mutation
(Lariviere et al., 2003).
Motor Neuron Death from Toxicity of Mutant SOD1
Not Loss of Dismutase Activity
SOD1 is an abundant, ubiquitously expressed cytosolic
enzyme. Since the known activity of SOD1 is to dismu-
tate (or convert) superoxide, a natural byproduct of
respiration, to water or hydrogen peroxide, the first
proposed pathogenic mechanism was the loss or
diminution of this detoxifying activity. However, animals
expressing dismutase active (hSOD1G37R [Wong et al.,
1995] and hSOD1G93A [Gurney et al., 1994; Howland
et al., 2002]) as well as inactive (hSOD1G85R [Bruijn et al.,
1997], mSOD1G86R [Ripps et al., 1995], hSOD1G127X
[Jonsson et al., 2004], hSOD1Quad [Wang et al., 2003],
hSOD1H46R [Nagai et al., 2001]) forms of the enzyme de-
velop comparable disease pathologies similar to that
seen in patients, including motor neuron synapse retrac-
tion (Fischer et al., 2004; Frey et al., 2000; Pun et al.,
2006), mitochondrial alterations (Higgins et al., 2003;
Kong and Xu, 1998; Liu et al., 2004; Wong et al., 1995),
and microglial activation (Boille´e et al., 2006; Engelhardt
and Appel, 1990; Hall et al., 1998; Henkel et al., 2006).
Furthermore, SOD1 gene deletion in mice does not
lead to motor neuron disease (Reaume et al., 1996). In
addition, deletion of the endogenous mouse SOD1 in
mice expressing dismutase inactive hSOD1G85R does
not affect disease course (Bruijn et al., 1998). Mice
expressing high levels of wild-type human SOD1
(hSOD1WT) transgene are healthy (Gurney et al., 1994;
Wong et al., 1995). Indeed, increased hSOD1WT, accom-
panied by chronic elevation of dismutase activity, has
either no effect on disease (Bruijn et al., 1998) or accel-
erates it (Deng et al., 2006; Jaarsma et al., 2000). Taken
together, these experiments have argued heavily
against the simple loss-of-function hypothesis.
SOD1 activity is dependent on a catalytic copper.
Since free copper is highly reactive and toxic, it must
be loaded onto SOD1 by a copper chaperone for
SOD1 (CCS; Corson et al., 1998; Wong et al., 2000b)
and subsequently held in place by a conserved disulfide
bond whose formation is catalyzed by CCS (Furukawa
et al., 2004). Since CCS is abundantly expressed in mo-
tor neurons (Rothstein et al., 1999) and motor neurons of
CCS-deleted mice have an increased sensitivity to axot-
omy-induced death (Subramaniam et al., 2002), it was
postulated that inefficient incorporation of copper into
SOD1 and/or a decreased shielding of copper (due to
changes in SOD1 structure as a result of mutation) could
provide an opportunity for aberrant copper-dependant
oxidative chemistry, yielding cellular damage and motor
neuron degeneration. This hypothesis was tested using
mice in which the incorporation of copper into mutant
SOD1 was significantly reduced by disruption of the
CCS gene. This did not slow disease course from either
dismutase active or inactive mutants (Subramaniam
Neuron
42et al., 2002). Furthermore, mice in which all four copper-
binding histidines have been eliminated (hSOD1Quad;
resulting in dismutase inactive SOD1) still develop typi-
cal ALS-like motor neuron disease (Wang et al., 2003).
Taken together, it is clear that the toxic property (or
properties) acquired as a result of SOD1 mutation (1)
are independent of dismutase and CCS activities and
(2) can be generated without catalysis by the active
site copper.
Misfolded SOD1 as a Common Feature
of ALS-Causing Mutations
Aggregates are a pathological hallmark of many differ-
ent neurodegenerative disorders including Alzheimer’s,
Parkinson’s, and Huntington’s diseases and ALS. Cyto-
plasmic protein aggregates are observed in both spo-
radic and familial ALS cases as well as in mutant SOD1
transgenic mice (Bruijn et al., 1997, 1998; Gurney et al.,
1994; Watanabe et al., 2001; Wong et al., 1995). That
said, use of the term ‘‘aggregate’’ is imprecise. In
some instances, it refers to abnormal accumulations of
intermediate filaments, including neurofilaments and
peripherin, as detected by immunostaining of spinal
cord tissue (Hirano et al., 1984b; Mendonca et al.,
2005; Mizusawa et al., 1989; Rouleau et al., 1996; Sobue
et al., 1990; Wong et al., 2000a). It has also been used to
define accumulations of detergent-insoluble forms of
proteins, including SOD1, that are detected by immuno-
blotting of filter-trappable material, as well as small
SOD1- or ubiquitin-positive fibrillar inclusions in spinal
cord sections (Deng et al., 2006; Furukawa et al., 2006;
Johnston et al., 2000; Jonsson et al., 2004, 2006; Wang
et al., 2003, 2005). Detergent-insoluble species are de-
tectable only in affected tissues of mutant SOD1 mice
and are most prominent at symptomatic stages (Furu-
kawa et al., 2006; Jonsson et al., 2006). A propensity to
form aggregates following synthesis of mutant SOD1
in primary cells is selective to motor neurons, as aggre-
gates were not produced in dorsal root ganglion (DRG)
or hippocampal neurons expressing similar levels of
mutants (Durham et al., 1997). The most misfolded un-
stable SOD1 mutants (with the shortest in vivo half-lives)
are most prone to aggregation (Wang et al., 2003).
A verycurious and unexplained aspectofdisease is that
the very unstable mutant hSOD1A4V (Sato et al., 2005),
which provokes a very aggressive disease course in hu-
mans, neither induces aggregates nor ALS-like disease
in mice, except in the context of high levels of hSOD1WT
(Deng et al., 2006). Similarly, increased hSOD1WT acceler-
ated disease from a second unstable mutant hSOD1L126Z.
In both cases, accelerated toxicity may be mediated
by stabilization of the mutant via heterodimerization
with hSOD1WT protein. Indeed, in both cases, increased
levels of hSOD1WT generated detergent-insoluble forms
of SOD1 that were not seen in spinal cord extracts of
hSOD1A4V or hSOD1L126Z mice alone.
Are SOD1 Aggregates Toxic?
Regardless of their definition or composition, the contri-
bution of aggregates to motor neuron toxicity remains to
be established. Indeed, it is unknown whether any of
these aggregates are indeed toxic. As introduced in Fig-
ure 1, proposals include aggregate-mediated inhibition
of the proteasome machinery, decreased chaperoneactivity, deregulation of organelle function including
Golgi, endoplasmic reticulum, and mitochondria, and
axonal transport defects possibly linked to aberrant
accumulations of intermediate filaments.
Aggregates found in ALS patients, as well as mouse
models, contain ubiquitin (Ince et al., 1998; Wang
et al., 2003; Watanabe et al., 2001), a protein adduct
which typically targets proteins for disposal via the pro-
teasome. Misaccumulation of ubiquitinated, misfolded
proteins might adversely affect the proteasome machin-
ery and impair normal protein degradation. Indeed, the
degradation of SOD1 itself and aggregates of SOD1 is
proteasome mediated (Basso et al., 2006; Niwa et al.,
2002; Urushitani et al., 2004; Urushitani et al., 2002).
While proteasome malfunction has been implicated in
motor neuron death, it is not yet established if it is a
cause or consequence of aggregate formation. Contra-
dictory results have been reported. In hSOD1G93A mice
which accumulate mutant protein to high levels, protea-
some activity is downregulated in the lumbar spinal cord
well before the development of symptoms (Kabashi
et al., 2004), while in a different line of mice with lower
accumulated levels of the same mutant, increased pro-
teasome activity in the spinal cord has been reported
at symptomatic stages (Puttaparthi and Elliott, 2005).
Protein misfolding is a probable initiator of aggregate
formation. Thus, many efforts have examined the protein
folding chaperone machinery, the heat-shock proteins
(HSPs), in the context of disease. In spinal cord extracts
of presymptomatic ALS mice, an overall decrease of
chaperone activity has been reported which persists
throughout disease course, and multiple recombinant
SOD1 mutants inhibit chaperone function in vitro (Bruen-
ing et al., 1999; Tummala et al., 2005). Paradoxically,
some HSPs, such as aB-crystallin and Hsp27 are
Figure 1. Proposed Toxicities of ALS-Causing SOD1 Protein Aggre-
gates
Cell machinery that might be affected by misfolded, mutant SOD1
includes coaggregation of essential cytoplasmic components, poi-
soning of the proteasome thereby inhibiting timely degradation of
many cellular proteins, saturation of cytoplasmic chaperones that
catalyze essential protein folding and refolding, and damaging
mitochondria by aggregation onto the cytoplasmic surface and/or
transport into the mitochondrial intermembrane space.
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43elevated in the spinal cords of hSOD1G37R and
hSOD1G93A mice, but Hsp27 is predominantly present
in glial cells in late disease stages (Vleminckx et al.,
2002; Wang et al., 2003). Hsp70, Hsp40, and Hsp90 are
also elevated but only in the spinal cords of hSOD1G85R
mice (Liu et al., 2005; Vleminckx et al., 2002; Wang
et al., 2003).
Motor neurons have a high threshold for induction of
the stress response, at least in vitro (Batulan et al.,
2003), which may contribute to their selective vulnerabil-
ity in ALS. Mutant SOD1-mediated depletion of HSPs is
a plausible possibility given that Hsp70 and Hsp25 pref-
erentially bind mutant SOD1 (Okado-Matsumoto and
Fridovich, 2002). Expression of several different HSPs
(Hsp70, Hsp40, Hsp27) in cultured cells and primary mo-
tor neurons decreases aggregate content and apoptosis
and improves axonal outgrowth (Bruening et al., 1999;
Patel et al., 2005; Takeuchi et al., 2002). Unfortunately,
applying this strategy in vivo by increased expression
of Hsp70 in four different mutant SOD1 mouse lines
did not ameliorate disease or pathology (Liu et al.,
2005). Induction of a broader stress response extended
life span in a small cohort of hSOD1G93A mice after treat-
ment with arimoclomol, a drug which induces the phos-
phorylation-mediated activation of the HSP inducing
factor HSF-1, thereby leading to increased levels of
Hsp70 and Hsp90 in spinal cords (Kieran et al., 2004). In-
terestingly, missense mutations in the gene encoding
Hsp27 have been identified in a number of families
with distal hereditary motor neuropathies and CMT neu-
ropathies (Evgrafov et al., 2004).
Mitochondrial Dysfunction as a Proximal Cause
of Motor Neuron Death
A common feature of many neurodegenerative diseases
is damage to mitochondria that contributes to the de-
generative phenotype. Mitochondria were implicated
as a possible target for toxicity in ALS by histopatholog-
ical observations of vacuolated and dilated mitochon-
dria with disorganized cristae and membranes in the
motor neurons (and muscle) of both sporadic and famil-
ial ALS patients (Afifi et al., 1966; Hirano et al., 1984a,
1984b). Mitochondrial defects have been reported in
spinal cords and muscle biopsies of patients ranging
from histopathological observations to impaired mito-
chondrial respiration and increased levels of uncoupling
proteins (Chung and Suh, 2002; Dupuis et al., 2003;
Echaniz-Laguna et al., 2002; Vielhaber et al., 1999;
Wiedemann et al., 2002). However, since all patients
tested were obligatorily symptomatic, it is difficult to de-
termine if these defects are primary or secondary to
muscle atrophy.
Mitochondrial abnormalities, especially multimem-
brane-containing vacuoles, are observed in the motor
neurons of mice that develop disease from accumula-
tion of dismutase active mutants (hSOD1G37R [Wong
et al., 1995] and hSOD1G93A mice [Dal Canto and Gurney,
1994; Higgins et al., 2003; Kong and Xu, 1998]) at very
early, presymptomatic stages (prior to any detectable
motor neuron loss or other observable damage (Higgins
et al., 2003; Kong and Xu, 1998; Wong et al., 1995). It has
been proposed that vacuole formation is due to expan-
sion of the mitochondrial intermembrane space and
consequent distention of mitochondrial membranes(Higgins et al., 2003). However, vacuoles inferred to de-
rive from degeneration of mitochondria have also been
described in mice with very high accumulated levels of
hSOD1WT protein (Jaarsma et al., 2000, 2001) which do
not develop disease and are absent in mice that develop
disease from dismutase inactive mutants (Bruijn et al.,
1997; Jonsson et al., 2006). Thus, vacuolation cannot
be a primary/common pathogenic mechanism for motor
neuron degeneration.
A proportion of the predominantly cytosolic SOD1
localizes to mitochondria in certain contexts. In both ro-
dent models and patient samples, mutant SOD1 is pres-
ent in fractions enriched for mitochondria derived from
affected, but not unaffected tissues (Bergemalm et al.,
2006; Deng et al., 2006; Liu et al., 2004; Vijayvergiya
et al., 2005). Mitochondrial localization of SOD1 has
been confirmed by electron microscopy in both isolated
mitochondria (Liu et al., 2004) and motor neurons in situ
(Higgins et al., 2002; Sasaki et al., 2004). SOD1 mutants
that cause disease at the lowest accumulated levels
(hSOD1G85R and hSOD1G127X; all dismutase inactive)
have the highest relative proportions that are mito-
chondrially associated (Liu et al., 2004). There is dis-
agreement in defining the submitochondrial compart-
ment(s) with which SOD1 is localized (or potentially
aggregated). Mutant SOD1 has been reported in both
the intermembrane space and the matrix, as well as
both the inner and outer membranes of spinal cord
and brain mitochondria (Bergemalm et al., 2006; Deng
et al., 2006; Higgins et al., 2002; Liu et al., 2004; Pasinelli
et al., 2004; Vijayvergiya et al., 2005). While these appar-
ent contradictions remain to be resolved, all reports
agree that SOD1 mutant proteins of divergent biochem-
ical characteristics localize to mitochondria, consistent
with a common contribution to pathogenesis.
Key questions are unresolved. Is there some intrinsic
feature of spinal cord mitochondria which permits SOD1
association and/or increases mitochondrial vulnerability
to mutant SOD1? Alternatively, is it the cytoplasmic
components of chaperone or proteasome activities
which confers some selectivity and facilitates mitochon-
drial association (Figure 1)? In which cell type(s), if any,
does mitochondrial association of the mutant play a cen-
tral role in pathogenesis? Of relevance here, the endog-
enous wild-type SOD1 protein is largely excluded from
spinal cord mitochondria, but all human SOD1 mutants
examined to date are mitochondrially associated. The
same human mutant proteins are largely excluded
from similar preparations of liver mitochondria (Liu
et al., 2004) despite a proportion of endogenous mouse
SOD1 localized to the intermembrane space of those
mitochondria (Liu et al., 2004; Okado-Matsumoto and
Fridovich, 2002). This discordance highlights that not
all mitochondria are created equally, as supported by
recent proteomic efforts profiling mitochondrial hetero-
geneity across tissues (Kislinger et al., 2006; Mootha
et al., 2003).
How mutant SOD1 affects mitochondrial function is
not yet clear, but differences in protein composition be-
tween mutant and nonmutant mitochondrial popula-
tions have been reported (Fukada et al., 2004; Kirby
et al., 2005; Lukas et al., 2006). It is important to note
that the mitochondrial genome itself encodes for only
thirteen of the estimated 1500 proteins required for
Neuron
44Figure 2. Mutant SOD1-Mediated Damage to Mitochondria
Mutant SOD1 is preferentially imported into or deposited onto mitochondria in affected tissues. The mechanisms by which mutant protein
might damage mitochondrial function are drawn. Mutant SOD1 may interfere with the elements of the electron transport chain, thereby disrupting
ATP-generating oxidative phosphorylation. Mutant SOD1 may also disrupt mechanisms by which mitochondria buffer cytosolic calcium levels.
Mutant SOD1 aggregates may interfere with components of mitochondrial-dependent apoptotic machinery, such as Bcl-2, thereby triggering
premature activation of an apoptotic cascade including cytochrome c release into the cytosol. Mutant SOD1 may indirectly affect similar path-
ways linked to mitochondria by physically blocking the protein import machines, TOM and TIM. Oxidative damage incurred by various mitochon-
drial proteins may also contribute to overall mitochondrial dysfunction. Collectively, these mechanisms (or a combination thereof) are predicted
to disturb cellular homeostasis (within glial and/or motor neurons), ultimately triggering motor neuron death.function. The majority of mitochondrial proteins are nu-
clear encoded and thus are synthesized in the cytosol
and subsequently transported into mitochondria. Import
of the majority of mitochondrial proteins is accom-
plished by membrane-spanning multisubunit transloca-
tors of the outer and inner membrane (TOM and TIM,
respectively). Mutant SOD1 associated with or aggre-
gated onto the mitochondrial surface could impede the
import machinery (Liu et al., 2004).
Many aspects of the electron transport chain, which
generates ATP via oxidative phosphorylation, have
been reported as either unchanged or altered, although
there is little or no consensus as to whether these activ-
ities are accentuated or attenuated. For example, ATP
synthesis has been reported as unchanged in aged
hSOD1G85R mice (Damiano et al., 2006) or depleted in
late symptomatic hSOD1G93A mice (Mattiazzi et al.,
2002), or ATP levels are depleted in presymptomatic
mice (Browne et al., 2006). Creatine, which extended
survival in hSOD1G93A mice by alleviating presumed en-
ergy deficits (Browne et al., 2006; Klivenyi et al., 1999),
was ineffective in human clinical trials (Groeneveld
et al., 2003; Shefner et al., 2004). Complex I activity
has been reported as elevated (Bowling et al., 1993;
Browne et al., 1998), reduced (Jung et al., 2002; Kirkine-
zos et al., 2005; Mattiazzi et al., 2002), and unchanged
(Damiano et al., 2006). Complex IV activity is reportedly
reduced, but only at very late disease stages (Kirkinezos
et al., 2005; Mattiazzi et al., 2002). Early impairment in
mitochondrial calcium-buffering capacity in mutant
SOD1 spinal cord prior to symptoms and only in dis-
ease-relevant tissues in two different mutant SOD1
models (Damiano et al., 2006) is perhaps the most per-
suasive of the efforts, since mitochondrial control of cal-
cium homeostasis is fully compatible with excitotoxicmechanisms that may be central to neuronal damage
(see Figures 2 and 3 and below).
Mitochondria: The Gatekeepers of Cell Death
Mitochondria are the gatekeepers of apoptosis, with
opening of the permeability transition pore and release
of cytochrome c central to the cascade of caspase acti-
vation. A final apoptotic mechanism is probably a central
aspect of neuronal death, as activation of the execu-
tioner caspase-3 is found in mouse models contempo-
raneous with neuronal death (Li et al., 2000; Pasinelli
et al., 2000) and lowered levels of the antiapoptotic
Bcl-2 have been reported in spinal cord motor neurons
of ALS patients (Ekegren et al., 1999; Mu et al., 1996)
and mutant SOD1 mice (Gonzalez de Aguilar et al.,
2000; Vukosavic et al., 2000). Intriguingly, it has recently
been demonstrated that caspase-3 activation in glial
cells proteolytically inactivates the glutamate trans-
porter EAAT2 (Boston-Howes et al., 2006). Since
EAAT2 is selectively lost during the disease process
and is considered to be a main participant in excitotox-
icity (which can trigger additional mitochondrial dys-
function), this provides an attractive mechanism by
which to unite mitochondrial dysfunction with excitotox-
icity (see later).
An alternate mechanism, in which SOD1 is proposed
to interact with Bcl-2 and possibly interferes with Bcl-2
antiapoptotic activity (Pasinelli et al., 2004), is attractive
but has recently been disputed (Gould et al., 2006). How-
ever, both constitutively increased expression of Bcl-2
(Kostic et al., 1997) and virally driven overexpression of
Bcl-2 in motor neurons (Azzouz et al., 2000) protect
motor neurons, delaying disease onset but not progres-
sion. Bcl-2 is unable to similarly rescue motor neuron
death in other models, such as wobbler and transgenic
Review
45Figure 3. Schematic of the Evolution of Motor Neuron Degeneration and Glial Activation during the Course of SOD1 Mutant-Initiated ALS Disease
Four stages are defined (normal, early phase, symptomatic, and end stage). Toxicity is non-cell-autonomous, produced by a combination of
damage incurred directly within motor neurons that is central to disease initiation and damage within nonneuronal neighbors, including astroc-
tyes and microglia, whose actions amplify the initial damage and drive disease progression and spread. Selective vulnerability of motor neurons
to ubiquitously expressed mutant SOD1 is determined by the unique functional properties of motor neurons (e.g., they are very large cells with
large biosynthetic loads, high rates of firing, and respond to glutamate inputs) and damage to their supporting cells in the neighborhood.mice expressing a point mutation in the NF-L gene
(Coulpier et al., 1996; Houseweart and Cleveland,
1999). Moreover, consistent with a similar outcome in
which intracerebroventricular (ICV) infusion of a broad
spectrum caspase inhibitor (Li et al., 2000) slowed mu-
tant SOD1-mediated neuronal death, disease onset
was also delayed in the absence of Bax, but progression
was unaffected (Gould et al., 2006), casting doubt on the
utility of antiapoptotic therapies.
Loss of the Neuromuscular Synapse as the First
Cellular Phenotype in ALS
The axon is the only means by which a motor neuron
communicates with its downstream target muscle,
both sending output information and receiving signaling
inputs from the muscle and other cells. Connection to
the muscle at the neuromuscular junction is lost in ALS
mouse models long before motor neuron degeneration
or death and the initiation of symptoms (Fischer et al.,
2004; Frey et al., 2000; Kong and Xu, 1998; Pun et al.,
2006). It has been long established in humans (Kawa-
mura et al., 1981) and in mice (Bruijn et al., 1997; Wong
et al., 1995) that it is the motor neurons that generate
large caliber (>5 mm) myelinated axons that are selec-
tively vulnerable in ALS. This important distinction has
now been refined with the demonstration that different
types of motor neurons, innervating different subsets
of muscle fibers, have different susceptibilities to mu-
tant SOD1 toxicity. Specifically, in two different mutant
SOD1 models, the fast-fatiguable motor neurons were
shown to be affected first, with denervation of their tar-
get muscles well before symptoms. Retraction of the
fast-fatigue-resistant motor neurons followed next,
with the slow type partially resistant to mutant SOD1
and actually attempting to reinnervate previously dener-
vated regions (Frey et al., 2000; Pun et al., 2006).A spontaneous dominant mouse mutant Wlds (Waller-
ian degeneration slow) significantly delays the degener-
ation of axonal segments located distal of an axonal cut
(axotomy; Glass et al., 1993; Perry et al., 1990). This is
due to a unique fusion protein containing the first 70 res-
idues of the ubiquitination factor UFD2/E4 joined to
mononucleotide adenylyltransferase (Nmnat), an en-
zyme that facilitates nicotinamide adenine dinucleotide
(NAD) synthesis (Conforti et al., 2000; Mack et al.,
2001). Despite conferring robust axonal protection in
neuropathy mouse models, including the peripheral
neuropathy model (pmn/pmn; Ferri et al., 2003) and
a model of myelin-related axonopathy (P0-deficient;
Samsam et al., 2003), Wlds failed to provide a benefit
in three different mutant SOD1 models (Fischer et al.,
2005; Vande Velde et al., 2004).
Damage within the Axon: Compromised Axonal
Transport in ALS
Motor neurons are among the most asymmetric cells in
nature, extending axons in humans that can be more
than a meter in length. Alterations in axonal structure
are well documented in both patients (Hirano et al.,
1984a, 1984b; Kawamura et al., 1981) and mutant
SOD1 mice (Bruijn et al., 1998; Kong and Xu, 1998;
Wong et al., 1995), especially the inappropriate misac-
cumulation of neurofilaments, the most abundant struc-
tural components of large myelinated axons. Neurofila-
ments are obligate heteropolymers of NF light (NF-L),
NF medium (NF-M), and NF heavy (NF-H) subunits and
interestingly, transgenic mice expressing a point muta-
tion in NF-L develop motor neuron disease (Lee et al.,
1994). Neurofilament accumulations are seen early in
mutant SOD1 mice (Kong and Xu, 1998). Removal of all
axonal neurofilaments by deletion of NF-L substantially
prolonged survival of hSOD1G85R and hSOD1G37R mice
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46(Nguyen et al., 2001; Williamson et al., 1998), as did re-
moval of most axonal neurofilaments by excessive
levels of NF-H (Couillard-Despres et al., 1998; Kong
and Xu, 2000; Nguyen et al., 2001). Since neurofila-
ment-dependent slowing of slow axonal transport is it-
self directly dependent on the phosphorylation state of
neurofilament tail domains (Ackerley et al., 2003), the in-
creased survival benefit likely derives primarily from re-
ducing the neurofilament-dependent burden on the ax-
onal transport machinery. This was demonstrated to
be the case by use of gene replacement to remove the
phosphorylated ‘‘tail’’ domains of NF-M and NF-H that
normally provide intra-axonal crosslinking of adjacent
filaments. Absence of those tail domains sharply slows
SOD1 mutant-induced disease (Lobsiger et al., 2005).
Consistent with this, a presymptomatic deficit of slow
axonal transport has been described in mutant SOD1
mice (Ackerley et al., 2003; Williamson and Cleveland,
1999, Zhang et al., 1997).
Additional evidence for a link between transport and
motor neuron disease arose from the discovery of a mu-
tation in the p150Glued subunit of dynactin in a family af-
fected with a slowly progressive, autosomal dominant
form of lower motor neuron disease (Puls et al., 2003).
p150Glued is responsible for providing processivity by
bridging between microtubules and cytoplasmic dynein
(Vaughan and Vallee, 1995; Waterman-Storer et al.,
1995), a motor powering retrograde axonal transport
along microtubules (Goldstein and Yang, 2000). Mice
heterozygous for either of two point mutations in dynein
have mispositioned hindlimbs, a phenotype reflected in
the names of the mutations, Legs at odd angles (Loa)
and Cramping1 (Cra1; Hafezparast et al., 2003). Surpris-
ingly, introducing either the Loa (Kieran et al., 2005) or
Cra1 (Teuchert et al., 2006) mutation to hSOD1G93A
mice significantly improves survival. This unexpected
amelioration of SOD1 mutant toxicity by a mutation ex-
pected to alter retrograde axonal transport is indeed
a conundrum that remains to be resolved.
Further genetic evidence implicating axonal transport
defects as a bona fide pathogenic mechanism in motor
neuron degeneration stem from additional mutations in
multiple genes relevant to transport in both human dis-
ease and mouse models. These include loss of the kine-
sin motor protein KIF1Bb as causative for CMT type 2A
(Zhao et al., 2001), loss of KIF5A in hereditary spastic
paraplegia (Reid et al., 2002), and loss of KIF21A in
a rare disorder affecting the oculomotor nerve (Yamada
et al., 2003). Mutations in genes involved in transport of
membranous vesicles include the ALS8 gene VAPB
(Nishimura et al., 2004b), Rab7 in CMT type 2B (Verho-
even et al., 2003), and Vps54 (vacuolar-vesicular protein
sorting 54) which is responsible for cervical motor neu-
ron degeneration in the wobbler mouse (Schmitt-John
et al., 2005).
The Neighborhood Matters: Non-Cell-Autonomous
Death of Motor Neurons
Although progressive paralysis in ALS arises from de-
generation and death of motor neurons, evidence from
several directions has converged to demonstrate that
toxicity is non-cell-autonomous. That is, toxicity to mo-
tor neurons derives from damage developed within cell
types beyond the motor neurons. Consistent with this,the known inherited forms are caused by mutations in
genes that are ubiquitously expressed (SOD1 and
VAPB) or expressed in multiple cells types (VEGF and
ANG). The initial evidence that damage within more
than one cell type was required for disease came from
expression of mutant SOD1 only within motor neurons
(Lino et al., 2002; Pramatarova et al., 2001) or astrocytes
(Gong et al., 2000). None of these efforts produced mo-
tor neuron degeneration or death (albeit the expression
of mutant SOD1 selectively within motor neurons might
have been at levels too low to initiate disease).
More definitive evidence emerged from construction
and analysis of chimeric mice that were mixtures of
hSOD1 mutant-expressing cells and normal cells (Clem-
ent et al., 2003). Some animals with only a small minority
of normal cells escaped disease, despite having high
proportions of mutant motor neurons. These efforts
conclusively demonstrated that expression of mutant
SOD1 within individual motor neurons, even at levels
that cause early onset, rapidly progressing disease
when expressed ubiquitously, is not sufficient to pro-
voke cell-autonomous degeneration or death of individ-
ual motor neurons of comparable ages.
Construction and analysis of mice carrying a deletable
(‘‘floxed’’) mutant SOD1 gene that can be excised by the
action of the Cre recombinase has identified differential
contribution of mutant damage within motor neurons
and nonneuronal neighbors in triggering disease onset
and progression (Boille´e et al., 2006). Excision of the
floxed mutant SOD1 gene exclusively within motor neu-
rons (by action of Cre recombinase expressed under
control of the motor-neuron-specific promoter Islet-1)
extended survival by slowing onset and an early phase
of disease progression. Similar findings by altering com-
ponents expressed only within neurons (i.e., gene dis-
ruption to remove all neurofilaments [Williamson et al.,
1998] or gene replacement to alter axonal structure
and volume after elimination of the tail domains of the
NF-M and NF-H subunits [Lobsiger et al., 2005]) provide
extended survival of SOD1 mutant mice but only by
slowing disease onset.
In contrast, diminishing mutant SOD1 levels within mi-
croglia and peripheral macrophages (using a Cre trans-
gene with a CD11b promoter that is expressed only
within the microglia and peripheral macrophage line-
ages) had little effect on early disease but sharply
slowed later disease progression, extending overall sur-
vival by 99 days. Similarly, in a complementary approach
the entire myeloid lineage was replaced by transplanta-
tion of normal bone marrow cells into SOD1 mutant mice
that were themselves unable to synthesize their own
myeloid cells due to deletion of the transcription factor
PU.1 (Beers et al., 2006). Transplantation at birth with
hSOD1G93A mutant-expressing myeloid cells (which
populate both the CNS and the periphery) produced
onset and survival typical of the hSOD1G93A mutant
line. Replacement of the microglial, monocyte, and
macrophage lineages with normal cells had no effect
on disease onset but slowed disease progression after
onset.
Thus, both approaches demonstrated that mutant
SOD1 within macrophages/microglial cells accelerates
disease progression, while mutant action within the
motor neurons is a primary determinant of onset and
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expressing microglial cells into control animals did not
give rise to motor neuron disease, demonstrating that
mutant SOD1-expressing macrophages/microglial cells
themselves are not sufficient to cause motor neuron
death.
It should be emphasized that a contribution of periph-
eral macrophages to accelerating disease progression
cannot be excluded. Indeed, a proportion of macro-
phages/microglial cells in the spinal cord of mutant
SOD1 mice have been shown to enter from the periphery
during the course of disease in mice (albeit this contribu-
tion seems minor [Solomon et al., 2006]). There is dis-
agreement whether replacing all of the peripheral, but
only a few of the spinal cord, myeloid derived cells by
bone marrow transplantation following irradiation is ben-
eficial in slowing disease (Corti et al., 2004; Solomon
et al., 2006). However, there is no uncertainty that replac-
ing both the peripheral and CNS microglial pools slows
disease progression after onset (Beers et al., 2006).
Contributions to toxicity developed within astrocytes,
the myelinating Schwann cells, or the target muscles
have not yet been established, although the ‘‘floxed’’
mutant transgene approach is well suited for such tests.
Targets for Therapy: Microglial Cells
as Determinants of Disease Progression
Microglial cells, the macrophages of the CNS, have been
long suspected as central components in neurodegen-
erative diseases where their role may include secretion
of trophic or toxic molecules. Their role in neuronal de-
generation during development is well established
(Marin-Teva et al., 2004). In ALS, microglial activation
has been described in the brain and spinal cord of pa-
tients (Engelhardt and Appel, 1990; Henkel et al., 2004;
Kawamata et al., 1992; McGeer et al., 1991; Troost
et al., 1993; Turner et al., 2004) and in the spinal cord
of different mutant SOD1 mouse models (Hall et al.,
1998; Henkel et al., 2006; Kriz et al., 2002). The microglial
reactivity is initiated before motor neuron loss (Henkel
et al., 2006). In addition, increased numbers of dendritic
cells, potent antigen-presenting cells implicated in the
immune response, have been reported in spinal cords
of ALS patients and hSOD1G93A mice during the disease
course (Henkel et al., 2006; Henkel et al., 2004).
Several groups have tried to treat motor neuron dis-
ease by using minocycline, a tetracycline derivative pre-
viously shown to inhibit microglial activation (Yrjanheikki
et al., 1999). Minocycline was potent in increasing sur-
vival of ALS mice and reduced microglial activation
(Kriz et al., 2002; Van Den Bosch et al., 2002; Zhu
et al., 2002). The primary effect of minocycline treatment
initiated in very young mice is a delay in disease onset
(Zhu et al., 2002), while administration closer to disease
onset results in a slowing of disease progression after
onset (Kriz et al., 2002). Regardless, both treatment par-
adigms provided a comparable extension of survival
(Kriz et al., 2002). Since minocycline also exerts an anti-
apoptotic property to neurons (Zhu et al., 2002), it is un-
clear in which cells the minocycline effect was active.
Either way, supported by its beneficial effect in ALS
mice, minocycline has been proposed for clinical trial
(Gordon et al., 2004; Pontieri et al., 2005).Cyclooxygenase-2 (COX-2), produced in abundance
by microglia and other inflammatory cells (but also by
neurons and astrocytes), plays a key role in stimulating
production of proinflammatory cytokines, and COX-2
expression is induced in spinal cords of ALS patients
(Yasojima et al., 2001; Yiangou et al., 2006). In mice,
use of a COX-2 inhibitor (celecoxib) prolonged survival
by slowing disease onset (Drachman et al., 2002) but
disappointingly did not alter progression after onset.
Subsequent test of celecoxib in a human trial failed to
provide a benefit in ALS (Cudkowicz et al., 2006).
Additional evidence implicating microglia in patho-
genesis of ALS arose from forcing activation of the im-
mune system using chronic administration of lipopoly-
saccharide (LPS), a well-known microglial activator.
Such treatment exacerbated SOD1 mutant-mediated
disease in mice (Nguyen et al., 2004). Similarly, inducing
microglial activation by deleting the fractalkine receptor,
a cytokine receptor expressed by microglia, mildly ac-
celerated neuronal loss in mutant SOD1 mice (Cardona
et al., 2006). Increased levels of several proinflammatory
factors have been described in the spinal cords of mu-
tant SOD1 mice even before motor neuron loss (Elliott,
2001; Hensley et al., 2003; Yoshihara et al., 2002). Cere-
brospinal fluid (CSF) and serum of ALS patients also
contain increased levels of inflammation related factors,
including complement proteins and monocyte chemoat-
tractant protein-1a (MCP-1a; Goldknopf et al., 2006;
Simpson et al., 2004).
One particularly interesting cytokine upregulated in
mutant SOD1 mouse spinal cords which could play
a role in motor neuron degeneration is tumor necrosis
factor-a (TNFa). TNFa has been shown to be produced
in higher levels by adult hSOD1G93A microglial cells
when stimulated with LPS compared to nontransgenic
microglial cells (Weydt et al., 2004). Administration of
a TNFa antagonist yielded a mild increase in survival in
mutant SOD1 mice (West et al., 2004). A direct toxic ef-
fect of activated microglial cells on motor neurons has
been shown in a coculture system and seemed to impli-
cate nitric oxide (Zhao et al., 2004). Microglial cells could
therefore be an important player in a Fas-ligand (FasL)-
induced apoptosis pathway within motor neurons that is
driven by nitric oxide synthesis (discussed in more detail
below). In addition, mutant SOD1, which has now been
reported to be released by motor neurons, is a potent
activator of microglial cells (Urushitani et al., 2006), em-
phasizing the likely crosstalk between motor neurons,
microglial cells, and potentially other nonneuronal cells
that may cooperate to drive disease progression.
An Outside-In Cascade Triggering a Cell-Death
Pathway Intrinsic to the Motor Neuron
At least a partial explanation for the selectivity of motor
neurons to SOD1 mutant toxicity has arisen from identi-
fication of a motor-neuron-specific cell-death pathway.
Not surprisingly, embryonic motor neurons extracted
from spinal cords of mutant SOD1 mice are more sus-
ceptible to toxic insults (Kruman et al., 1999; Raoul
et al., 2002; Spalloni et al., 2004b; Van Den Bosch
et al., 2004) and have modified electrophysiology and al-
tered excitability (Pieri et al., 2003; Spalloni et al., 2004a)
compared to neurons from normal mice or mice ex-
pressing high levels of hSOD1WT protein. These neurons
Neuron
48also have what has been proposed as a motor-neuron-
specific cell-death pathway downstream of the Fas
death receptor. Increased susceptibility to death trig-
gered by the Fas receptor requires nitric oxide, the Fas
death domain-associated protein Daxx, and p38 kinase
activation, which subsequently drives nitric oxide pro-
duction, thus generating a feed-forward amplification
loop (Raoul et al., 1999, 2002, 2006). Cultured motor neu-
rons from transgenic mutant SOD1 mice have an in-
creased susceptibility to activation of this pathway,
which is apparently also activated in presymptomatic
ALS mice (Raoul et al., 2002, 2006; Wengenack et al.,
2004). Given the acceleration of disease by mutant mi-
croglia, it is plausible that SOD1 mutant-induced release
of nitric oxide by microglia drives this death cascade
within motor neurons.
Astrocytes in ALS: Gatekeepers of Synaptic
Glutamate and Excitoxicity
Astrocytes are essential partners of motor neurons, pro-
viding them with trophic support and mediating rapid re-
covery of synaptic glutamate through the action of the
glial glutamate transporter EAAT2 (also referred to as
GLT-1 in rodents). Astrocytes insert finger-like pro-
cesses loaded with this transporter into and surrounding
synapses, thereby facilitating rapid removal of synaptic
glutamate following its release from the presynaptic
terminal (as detailed in Figure 3). Glutamate-mediated
excitotoxicity can induce neuronal damage and death
as a consequence of repetitive firing, which in turn
drives calcium entry through calcium-permeable AMPA
glutamate receptors. Within the spinal cord, preventing
glutamate-driven excitotoxicity is primarily the job of as-
trocytes. Motor neurons have an inherently high sensitiv-
ity to excitotoxicity since their glutamate receptors have
a lower proportion of the GluR2 subunit (Van Damme
et al., 2002) relative to many other types of neurons. Reg-
ulation of the Ca2+ permeability properties of GluR2 is
due to posttranscriptional RNA editing, with only AMPA
receptors containing edited GluR2 resistant to Ca2+ en-
try. Already with low GluR2 levels, the efficiency of
mRNA editing is reduced in the spinal cord motor neu-
rons of ALS patients compared to controls (Kawahara
et al., 2004; Takuma et al., 1999). Altered efficiency of ed-
iting was not found in hSOD1G93A or hSOD1H46R rats (Ka-
wahara et al., 2006), thereby demonstrating that change
in mRNA editing is not required for familial disease.
Astrocytes also respond to damage in many settings
by what is referred to as activation. This includes an in-
crease in assembly of their intermediate filaments (as-
sembled from glial fibrillary acidic protein, GFAP) and
an increase in the number and size of processes ex-
tended from the cell body (Figure 3). Astrocyte activa-
tion is seen in spinal cords of ALS patients and SOD1
mutant mice (Hall et al., 1998; Levine et al., 1999; Schiffer
et al., 1996). Indeed, for mice expressing the dismutase
inactive mutant hSOD1G85R, a very prominent early pa-
thology that increases markedly during disease course
is the presence of SOD1-containing inclusions within
activated astrocytes (Bruijn et al., 1997).
Altered glutamate handling is one of the few firm
mechanistic links between sporadic and SOD1 mutant-
caused ALS. Diminished glutamate transport has been
reported in synaptosomes obtained from affected CNStissues of ALS patients (Rothstein et al., 1992), and
levels of EAAT2 are reduced in the motor cortex and spi-
nal cord of ALS patients (Fray et al., 1998; Maragakis
et al., 2004; Rothstein et al., 1995; Sasaki et al., 2000),
spinal cords of mutant SOD1 mice (Bruijn et al., 1997)
and rats (Howland et al., 2002), as well as in a model of
Sindbis virus-induced motor neuron disease (Darman
et al., 2004). This is functionally of consequence for
familial ALS in that hSOD1G93A mice heterozygous for
EAAT2 develop earlier-onset disease (Pardo et al.,
2006), while drugs that increase EAAT2 activity extend
survival (Ganel et al., 2006; Rothstein et al., 2005). In-
deed, screening of FDA-approved drugs for those
that could elevate EAAT2 activity has identified a
CNS-penetrating b-lactam antibiotic, ceftriaxone, as a
transcriptional inducer that modestly extends survival
in hSOD1G93A mice (Rothstein et al., 2005). An inhibitory
effect on quantal glutamate release is also believed to
underlie the mild slowing of disease course in human
ALS from the only FDA-approved treatment (riluzole;
Doble, 1996).
Additional implication for an astrocytic contribution in
ALS is demonstration in cell culture that activated astro-
cytes induce embryonic motor neuron degeneration via
their production of NGF, which in the presence of low
concentrations of nitric oxide can induce apoptosis of
motor neurons through the p75NTR receptor. Indeed, rel-
ative to resting astrocytes, activated astrocytes in the
spinal cord of hSOD1G93A mice have increased NGF syn-
thesis (Pehar et al., 2004).
Muscle Involvement in ALS: Targets for Therapy?
Among the earliest events in the human ALS- and SOD1-
mediated disease is withdrawal of the motor axons from
the neuromuscular synapse (Fischer et al., 2004; Frey
et al., 2000; Pun et al., 2006; Schaefer et al., 2005). This
denervation generates the progressive paralysis of ALS,
a consequence of which is muscle atrophy (Cifuentes-
Diaz et al., 2001). Mutant SOD1 is also expressed by
muscle, but whether its presence there contributes to
pathogenesis is not yet established.
A test of whether enhanced muscle mass and strength
per se can be beneficial in ALS has been attempted by
repetitive injection into hSOD1G93A mice of an antibody
to myostatin, a secreted protein whose action inhibits
muscle growth. Initiated before disease onset, this pro-
duced enhanced muscle mass initially, but the effect on
limb muscles was short lived, yielding neither a survival
benefit nor preservation of muscle mass throughout dis-
ease progression (Holzbaur et al., 2006).
On the other hand, muscle hypertrophy induced by
agents such as insulin-like growth factor-1 (IGF-1) or
growth hormone (Dobrowolny et al., 2005; Kaspar
et al., 2003, 2005) has led to significant life extensions
in ALS transgenic mice. For the IGF-1 studies, not only
was there muscle hypertrophy but also concomitant
stimulation of muscle satellite cell proliferation and an
increase of centrally nucleated muscle fibers, indicating
regeneration. Although in one instance IGF-1 synthesis
was mediated by a transgene expressed only by the
muscle (Dobrowolny et al., 2005), it has not been estab-
lished if the secreted IGF-1 acts on the muscle, the mo-
tor neuron, or both. At a minimum, these efforts illustrate
the possibility of using trophic factor synthesis by
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49muscle (see section below) as a way of rescuing
motor neurons. Added to this, a number of studies
have shown that exercise is beneficial in ALS transgenic
animals (Kirkinezos et al., 2003; Veldink et al., 2003),
with exercise and IGF-1 exhibiting a synergistic effect
resulting in an increase in median life span by 83 days
(Kaspar et al., 2005). The mechanism underlying this
synergism is not known, and the relevance for human
ALS unclear, as no consensus has emerged from several
efforts to evaluate a benefit of exercise in human
disease (Drory et al., 2001; Pinto et al., 1999; Scarmeas
et al., 2002).
A Model for Selective Vulnerability of Motor
Neurons in ALS
Combining the lessons from multiple animal models
used a determine pathogenic mechanisms in inherited
ALS, the central insight is that although motor neuron
degeneration and death is the primary cause of the pro-
gressive paralysis, toxicity is produced by damage
developed not only within motor neurons, but also by
other nonneuronal neighbors (Figure 3).
Onset and Early Phase
Damage directly within motor neurons is an important
determinant of disease onset. The earliest event, prior
to disease symptoms, is retraction of motor axons
from their synapses onto muscles. During this phase,
mutant SOD1 primarily acts directly within motor neu-
rons, with aggregation of misfolded SOD1 damaging
cellular machinery, especially mitochondria, so as to in-
hibit one or more normal functions. Anterograde axonal
transport is also inhibited, as the consequence either of
mitochondrial damage or of disorganization of axonal
neurofilaments. SOD1 mutant action within the motor
neuron is amplified by action within other cell types,
especially the microglia which respond to the initial
damage by amplifying it, thereby driving more rapid dis-
ease progression and spread.
Symptomatic
The symptomatic phase is characterized by a massive
activation of microglia and astrocytes, in addition to
continuing damage within motor neurons themselves.
Misfolded SOD1 mutant within astrocytes, as well as
their activation in response to neuronal damage, in-
duces loss of the EAAT2 glutamate transporter, reduc-
ing rapid recovery of synaptic glutamate and driving
an excitotoxic response that includes excessive influx
of Ca2+ during repetitive firing of glutamate receptors
on motor neurons. SOD1 mutant action directly within
microglial and astrocytic cells may provoke reduced se-
cretion of trophic molecules or increased release of
toxic factors (e.g., nitric oxide, TNFa, or mutant SOD1
secreted or released by cell leakage or lysis). The latter
molecules drive spread of toxicity to neighboring cells.
Mutant SOD1 can itself activate microglia. In return,
microglial cells, through secretion of toxic factors,
harm their environment, including motor neurons.
End Stage
At end stage, denervation has produced paralysis ac-
companied by muscle atrophy. Activated microglia or
astrocytes produce diffusible toxic products, including
nitric oxide and/or TNFa, which accelerate disease
spread. Loss of EAAT2 glutamate transporters from as-
trocytes drives repetitive firing of glutamate receptorsand an ensuing excitotoxicity that is accompanied by
excessive Ca2+ entry that further damages mitochondria
and finally triggers a caspase-dependent cell suicide
pathway within motor neurons.
Thus, selective sensitivity of motor neurons to ubiqui-
tously expressed SOD1 mutants derives from the com-
bination of risk factors shared by those neurons and
their most intimately associated cellular neighbors.
Seen this way, it is clear that the question is not whether
the mitochondrial damage and ensuing oxidative dam-
age hypothesis is right, any more than it is whether the
hypotheses for glutamate-linked excitotoxicity, axonal
transport clogging, loss of trophic support, or excessive
release of toxic species are right. All these mechanisms
(which have also been invoked in sporadic ALS) are right
and all combine to underlie selective vulnerability. This
is very good news for the design of therapies: inter-
vention at any of these steps can, in principle, disrupt
the toxic cascade between the motor neuron and its
neighbors.
Growth Factor Therapies in ALS
Use of trophic factors has dominated recent efforts in
clinical trials in ALS. All of these efforts were predicated
on the hope that whatever the primary disease provok-
ing insult, provision of increased levels of factors that
could be trophic for motor neurons would be of benefit.
These have lead to nearly uniform disappointment, pro-
viding little or no benefit for IGF-1 (Borasio et al., 1998;
Lai et al., 1997) and no benefit for BDNF (BDNF Study
Group, 1999) or CNTF (ALS CNTF Treatment Study
Group, 1996). Aside from the absence of evidence that
growth factors were limiting in ALS, the weakness of
these approaches was insuring adequate delivery to
the right cells. One method for eliminating blockage of
drug delivery by the blood-brain barrier is direct, contin-
uous infusion into either the brain (ICV) or spinal cord
(intrathecal; Figure 4B). Continuous intrathecal adminis-
tration of BDNF was found to be without benefit, but ICV
infusion of IGF-1 extended survival in mice (Nagano
et al., 2005a), and a phase I clinical trial using the same
strategy showed a modest benefit to patients without
adverse effects (Nagano et al., 2005b).
In animal models, efficacy in growth factor delivery
has been achieved by either of two approaches: viral-
mediated gene delivery to convert target cells into facto-
ries that secrete trophic factors and infusion of trophic
molecules directly into the brain or spinal cord (Figure 4).
For the first approach (Figure 4A), an IGF-1-encoding
gene was inserted into adenoassociated virus (AAV),
a small replication-defective virus that is episomally
maintained within the nucleus of a host cell. Injection
into muscle yielded viral expression within motor neu-
rons for at least 1 year. Use of this strategy slowed
disease progression in hSOD1G93A mice even when initi-
ated after disease onset (Kaspar et al., 2003). Not sur-
prisingly, success required the right trophic factor. The
same AAV producing GDNF used in the same manner
provided only a very modest benefit (Kaspar et al.,
2003), consistent with prior efforts using GDNF encoded
by adenovirus (Acsadi et al., 2002) or AAV (Wang et al.,
2002) delivered intramuscularly.
With the potential that variants in the VEGF gene con-
tribute to some examples of ALS (Table 1), delivery of an
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50Figure 4. New Directions for Therapies in
ALS Using Viral Delivery or Direct Infusion
into the Brain or Spinal Cord
(A) Delivery by injection into muscle of viral
particles (AAV) encoding trophic factors
such as IGF-1 or VEGF. Viral particles are
taken up at the synapse by the motor neuron
terminal and retrogradely transported to the
motor neuron cell body in the spinal cord.
After translocation into the nucleus, the epi-
somal viral genome is stably expressed for
at least 1 year, converting motor neurons
into factories for secretion of trophic factors.
Trophic factors could also be synthesized
directly in the muscle, increasing their sup-
port of the motor neuron terminal. This ap-
proach is also suitable for viral delivery of
transcription-based siRNA approaches in
which mutant SOD1 mRNAs (or specific cel-
lular mRNAs) are targeted for degradation
selectively within motor neurons. An alterna-
tive is for direct injection of viral particles
into the spinal cord. This approach is more in-
vasive but has the advantage of targeting not
only the motor neurons but also nonneuronal
neighboring cells of the motor neurons.
(B) Direct infusion into the spinal cord (intra-
thecal) or brain (intracerebroventricular, ICV)
of trophic factors directly into the CSF yields
widespread delivery throughout the brain and
spinal cord. Alternatively, ICV infusion of anti-
sense oligonucleotides can reduce mutant
SOD1 by targeting intranuclear degradation
of its mRNA both within the motor neurons
and the surrounding microglial and astrocytic
cells.integrating lentivirus encoding VEGF (and pseudo-
coated so as to be retrogradely transported) extended
survival of hSOD1G93A mice (Azzouz et al., 2004). So
too did continuous ICV infusion of recombinant VEGF
protein into the CSF (Figure 4B): disease onset was de-
layed and survival extended by 22 days (Storkebaum
et al., 2005). This ICV delivery of VEGF was especially ef-
fective in slowing forelimb paralysis, suggestive of
a higher concentration of VEGF closer to the site of infu-
sion. A modest benefit was seen even when VEGF treat-
ment was initiated after symptomatic onset. Unresolved
is which cells are targeted by this VEGF. Weekly intra-
peritoneal injection of VEGF also has been reported to
slow disease in hSOD1G93A mice (Zheng et al., 2004),
raising the possibility that important target cells are out-
side the CNS, including those in the vasculature.
Gene Therapies in ALS
With recognition that the instances of ALS caused by
dominant mutation in SOD1 derive from a toxic property
of the mutant protein and that even complete absence of
dismutase activity (by gene deletion) does not cause
overt disease in mice (Reaume et al., 1996), strategies
to limit the synthesis of the mutant gene product have
become an increasingly realistic possibility. Two general
strategies have been used: virally delivered, transcrip-
tion-based RNA silencing (siRNA), and direct infusion
of antisense oligonucleotides (Figure 4).Three efforts using siRNA to catalyze degradation of
the mRNA encoding SOD1 have proven successful in
hSOD1G93A mice. In the most comprehensive, a lentivi-
rus encoding such an siRNA was injected into multiple
muscles of very young mice (an age equivalent to inject-
ing infants in humans). After retrograde transport to mo-
tor neuron cell bodies, reducing SOD1 mutant synthesis
in motor neurons had a remarkable effect in slowing dis-
ease initiation (108 days) and extending overall survival
by 99 days (Ralph et al., 2005). Despite sharply delayed
disease onset through gene silencing within motor neu-
rons but not other cells of the CNS, disease progression
was not slowed at all, with animals reaching endstage
w25% faster in the treated animals (Ralph et al., 2005).
Similar slowing of disease onset was seen by retrograde
delivery of an siRNA-encoding AAV (Miller et al., 2005).
Direct viral injection of a similar siRNA virus into the
spinal cord (to target both motor neurons and their non-
neuronal neighbors) delayed degeneration of motor
neurons near the site of injection but it could not be de-
termined whether this affected disease progression
(Raoul et al., 2005).
In considering extension of such viral efforts to the hu-
man setting, substantial practical issues remain. Current
viral vectors provide no mechanism for altering dosage
or discontinuance of therapy and face significant chal-
lenges for reaching widespread areas of the CNS. An
alternative approach that surmounts both of these is
targeted mRNA degradation after direct ICV delivery of
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51synthetic antisense oligonucleotides into the CNS.
Small (15–25) nucleotide sequences of DNA bind by
Watson-Crick hybridization to a target mRNA in a se-
quence-specific manner. The mRNA in such a heterodu-
plex is a substrate for catalytic, intranuclear degradation
by endogenous RNase H. This approach has been suc-
cessfully used for lowering mutant SOD1 levels by
w50% throughout the brain and at all levels of the spinal
cord of hSOD1G93A rats. Initiated near disease onset,
this approach successfully slowed progression after on-
set (Smith et al., 2006), a benchmark for a human ther-
apy. Similar ICV administration to nonhuman primates
demonstrated effective delivery to both the motor neu-
rons and nonneuronal neighbors throughout the brains
and spinal cords (Smith et al., 2006). These efforts es-
tablish that direct delivery of antisense oligonucleotides
can be an effective, dosage-regulatable means of treat-
ing neurodegenerative diseases, including ALS. Added
to this, direct infusion of siRNA duplexes, assuming is-
sues of stability can be surmounted, add an additional
therapeutic possibility, including the ability to target
a mutant-encoding mRNA without affecting the wild-
type mRNA (Xia et al., 2006).
Stem Cell Therapies in ALS
The selective, age-dependent killing of motor neurons
has made ALS one of the poster diseases for cell re-
placement using stem cells. Replacement of human mo-
tor neurons, however, faces daunting challenges. The
lower motor neurons have their cell bodies scattered
throughout the length of the spinal cord, so that any
cell replacement might require multiple spinal injections
at all levels of the cord. Further, even if the developmen-
tal program can be achieved and issues of inhibition of
axonal extension within the CNS are overcome, re-
growth and correct targeting of meter-long axons will
require at least a year (assuming the maximal rate of
human axonal extension observed in early postnatal
development).
These issues not withstanding, recent successes
have overcome several of the important hurdles to
the feasibility of a stem cell replacement strategy after
acute motor neuron killing induced by Sindbis virus
exposure (Deshpande et al., 2006; Harper et al., 2004).
In a first series of experiments, mouse embryonic stem
(ES) cells were differentiated into motor neuron precur-
sors and were injected into rat spinal cords paralyzed
by Sindbis virus exposure. A quarter (w3000 cells) of
the in vitro differentiated, ES cell-derived motor neurons
survived within the spinal cord and even a few of them
extended axons into the ventral roots, but only when
the rats were infused intrathecally with molecules known
to alleviate myelin repulsion of axonal growth. However,
neuromuscular junctions were not formed (Harper et al.,
2004).
Altered differentiation conditions subsequently pro-
duced higher numbers of motor neurons derived from
the ES cells and produced not only neuromuscular con-
nections but relieved paralysis of Sindbis virus-exposed
rats (Deshpande et al., 2006). A key improvement seems
to be use of dibutyryl-cAMP as an anti-myelin repulsion
factor and grafting of neural stem cells expressing glial-
derived neurotrophic factor (GDNF) into the nerve.
Transplantation of ES cells that had not been previouslydifferentiated into motor neurons showed that the
grafted motor neurons themselves, rather than other
surviving derived stem cells, account for the improve-
ment. Whether this strategy will be successful in a model
of chronic motor neuron degeneration, such as ALS, re-
mains to be determined.
Other strategies with hSOD1G93A mice have used (1)
human neural stem cells grafted into the spinal cord
(Yan et al., 2006), (2) human umbilical cord blood cells
transfused into the systemic circulation (Garbuzova-
Davis et al., 2003), or (3) bone marrow transplant (Corti
et al., 2004), and each has been reported to provide
some extension in survival (Corti et al., 2004). One study
reported an early protection of motor neurons which
was not sustained at end stage (Corti et al., 2004).
An alternative strategy is the idea of stimulating the
endogenous pool of stem cells for replacement of de-
generating motor neurons. In hSOD1G93A mice, an in-
crease in neural progenitor cell proliferation, migration,
and neurogenesis in the lumbar region of the spinal
cord has been observed in response to motor neuron
degeneration (Chi et al., 2006). Furthermore, the endog-
enous recruitment of neural progenitors (as determined
by nestin staining) was initiated on the predominantly
symptomatic side of asymmetrically paralyzed
hSOD1G93A rats (de Hemptinne et al., 2006). Whether
endogenous neuroprogenitors could be used for
generating new motor neurons is not yet established, al-
though examination of the neural stem cell/neuroproge-
nitor niches of the forebrain has revealed alterations in
hSOD1G93A mice (Liu and Martin, 2006). It must also be
recognized that any new neurons produced by such an
approach will obligatorily express mutant protein and
will also be at risk.
Finally, with the recognition of non-cell-autonomous
contributions to motor neuron toxicity (Boille´e et al.,
2006; Clement et al., 2003), other stem cell strategies
to replace nonneuronal precursors, including those en-
gineered to produce trophic factors such as IGF-1, are
now sensible approaches.
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